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Abstract
Mucinous epithelial ovarian cancers are clinically and morphologically distinct from the other
histopathologic subtypes of ovarian cancer. Unlike other ovarian subtypes, epidemiologic studies
have indicated that tobacco exposure is a significant risk factor for developing mucinous ovarian
cancer. Detection of autoantibody reactivity is useful in biomarker discovery and for explaining the
role of important pathophysiologic pathways in disease. In order to study if there are specific antibody
biomarkers in the plasma samples of mucinous ovarian cancer patients, we have initiated a screen
by employing a “reverse capture antibody microarray” platform that uses native host antigens derived
from mucinous ovarian tissues as “baits” for the capture of differentially labeled patient and control
autoantibodies. 35 autoantibodies that were significantly elevated in the cancer plasma samples
compared with healthy controls, and six autoantibodies that segregated smoking and nonsmoking
patients were identified. Functional annotation of the antibody targets has identified nine target
antigens involved in integrin and Wnt signaling pathways. Immunohistochemistry of archived
ovarian specimens showed significant overexpression of eight of the nine target antigens in mucinous
ovarian tumor tissues, suggesting that plasma autoantibodies from mucinous ovarian cancer patients
might have heightened reactivities with epitopes presented by these overexpressed antigens.
Autoantibody profiling may have an unexpected utility in uncovering key signaling pathways that
are dysregulated in the system of interest.
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1. INTRODUCTION
Ovarian cancer accounts for more than half of the deaths due to gynecological malignancy
(1). Because of lack of sensitive tests for the detection of early stage disease, which is often
without prominent symptoms, 75% of malignant epithelial ovarian tumors are detected in late
stage, with a 5-year survival rate of about 30% (2). Ovarian cancer is morphologically classified
into four major subtypes: serous, mucinous, clear cell, and endometrioid (3). Mucinous tumors
comprise 12-15% of epithelial ovarian cancers. They are cystic tumors with locules lined with
mucin-secreting epithelial cells resembling either endocervical or colonic epithelium.
According to the World Health Organization classification, mucinous ovarian tumors are
categorized as cystadenomas, borderline tumors, noninvasive intraglandular and intraepithelial
carcinomas, invasive carcinomas, and metastatic from other sites. While invasive mucinous
carcinomas account for only 10% of epithelial ovarian cancers, 27% of patients with stage I
epithelial ovarian cancer have mucinous pathology (4). Primary mucinous ovarian tumors are
usually distinguished immunohistochemically by positive staining for cytokeratin 7 and
negative staining for cytokeratin 20 (5).
Molecular and clinical studies have shown that mucinous ovarian tumors are distinct from other
ovarian tumor subyptes in etiologic pathways, response to chemotherapy, and outcome for
patients. Unlike the more common serous subtype, mucinous ovarian tumors are not associated
with p53, BRCA1 or BRCA2 mutations, have frequent k-ras mutations and modest ratio
between the serum markers CA125 and carcinoembryonic antigen CEA (5). Molecular and
pathologic studies also support a progression model for the development of mucinous ovarian
tumors (6). Transitions between benign and malignant areas are seen in 80% of malignant
mucinous adenocarcinomas. Identical k-ras mutations are frequently found in coexisting
borderline and invasive epithelia within a mucinous tumor (7,8). Gene expression profiling
also identified co-regulated genes shared between cystadenomas and invasive mucinous
tumors (9), supporting the view that invasive tumors are evolved from the benign disease.
Patients with mucinous ovarian cancer were treated with standard platinum-taxane regimens
like the other histologic types. However, advanced mucinous ovarian adenocarcinomas show
poor response rates of 26-42% to first-line platinum-based chemotherapy (10). In addition,
many multicenter, population-based, case-control investigations in ovarian cancer have
indicated that women with smoking exposure have significant risk of developing mucinous
ovarian cancer (11-13). The adjusted odds ratio of smoking exposure to mucinous cancer
development ranged from 1.5 to 3.2, with the current smokers having the highest risk. Similar
patterns of elevated risk were not observed among other ovarian histologic types. Extensive
studies on the etiology of smoking-related mucinous ovarian cancer should be beneficial for
cancer prevention and cancer therapies.
Recent human whole genome sequencing projects have revealed that human cancers are
characterized by deregulations of a few core signaling pathways (14,15). Identification of these
key signaling pathways is essential for the understanding of pathogenic mechanisms and
targeted therapeutic development. It is well known that cancer patient sera contain antibodies
that react with a unique group of autologous cellular antigens called tumor-associated antigens
(16,17). These autoantibodies, together with T cell responses, represent the adaptive immune
response to tumor-associated antigens in cancer patients (18). Detection of autoantibody
reactivity is useful in biomarker discovery and for explaining the role of important pathways
in the pathophysiologic development of diseases. Recent studies on tumor-associated antigen-
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induced autoantibodies have demonstrated that the titers of some autoantibodies were
significantly elevated several years before the diagnosis of cancer and therefore can serve as
an early signal of increased risk of developing cancer (19-21). These characteristics of
autoantibodies highlight the potential in evaluating cancer risk and early cancer detection.
There are multiple platforms to compare the whole serum autoantibody repertoires between
tumor patients and normal controls (22). The most commonly used method is the use of
autoimmune serum in the serological analysis of recombinant cDNA expression libraries
(23) or recently of high-density protein microarrays (24). However, this strategy fails to identify
autoantibodies that target low abundance proteins and peptides generated from enzymatic
cleavages or degradations; recombinant proteins generated from the cDNA library may also
lack posttranslational modifications and native configuration necessary for the antibody
recognition. Other proteomic methods are either labor intensive or require expensive
equipment such as mass spectrometry. (25-27). We have applied an innovative reverse-capture
antibody array platform that uses tumor tissue-derived native protein antigens captured on an
antibody microarray to profile autoantibody biomarkers in mucinous ovarian cancer plasma
samples. We have also analyzed the expression levels of the target antigens that may suggest
deregulation of key signaling pathways in the pathogenesis of mucinous ovarian cancer.
2. MATERIALS AND METHODS
2.1. Clinical Specimens
The ovarian plasma and tissue samples for this study were selected from the Ob/Gyn
Epidemiology Center and tumor bank at the Laboratory of Gynecologic Oncology at Brigham
and Women’s Hospital. The plasma samples collected at the Ob/Gyn Epidemiology Center
were from a population-based case-control study of ovarian cancer, and a NIH Early Detection
Research Network (EDRN) pre-operative/post-operative study. The studies were approved by
the Brigham and Women’s Hospital and Dartmouth Medical Center’s Institutional Review
Boards. The normal controls were identified and invited through town books in Massachusetts
and Drivers’ License lists in New Hampshire and sampled to match the age and residence of
the tumor cases. The tumor tissues collected at the Laboratory of Gynecologic Oncology at
Brigham and Women’s Hospital used protocols approved by the Institutional Review Boards.
The histopathological characteristics of the samples were provided by specialists in
gynecologic pathology. Patient’s consent was obtained before the collection of clinical
samples.
2.2. Reverse capture antibody array profiling using tumor tissue-derived native antigens
The detailed protocols can be found in published references (28,29), with minor modifications.
Briefly, human IgG was isolated from 20 microliters of each cancer plasma sample using the
Melon™ Gel IgG Spin Purification Kit (Pierce Biotechnology, Rockford, IL), according to the
manufacturer’s instruction. The control IgG was pooled from 20 age-matched healthy women.
100 micrograms of purified cancer and control IgGs were labeled for 45 minutes with Cy3 and
Cy5 mono-Reactive Dye Packs (GE Healthcare Bio-Sciences Corp., Piscataway, NJ),
respectively, in Extraction/Labeling Buffer from the Ab Microarray Express Buffer Kit
(Clontech Laboratories Inc, Mountain View, CA). Uncoupled Flours were removed by using
the Zeba™ Desalt Spin Columns (Pierce Biotechnology, Rockford, IL). For native antigen
preparation, 200 mg of frozen tissue were ground with 0.5 g of alumina in a mortar. 1-2 ml of
prechilled Extracted/Labeling Buffer was added and the paste was centrifuged to collect the
supernatant. Protein concentrations of the extracts were determined using microBCA Protein
Assay Reagent Kit (Pierce Biotechnology, Rockford, IL). For each microarray incubation, 200
μg of protein extracts were diluted in 5 ml of Incubation Buffer provided by the Ab Microarray
Express Buffer Kit (Clontech Laboratories Inc, Mountain View, CA), and applied to the AB
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Microarray-500 slide (Clontech Laboratories Inc, Mountain View, CA). After incubation for
45 min at room temperature with gentle rocking, the array slide was washed three times with
phosphate-buffered saline (PBS). 100 μg of each labeled cancer plasma IgG were combined
with equal amounts of pooled labeled control IgG and added to each slide and allowed to
hybridize at room temperature for 45 minutes. The array was then washed with the Wash
Buffers provided by the Ab Microarray Express Buffer kit, once with water, spin-dried, and
scanned with a ScanArray 4000XL scanner (Perkin Elmer, Waltham, MA) to obtain Cy5 and
Cy3 images. To confirm the microarray results for each cancer plasma sample, another
microarray incubation was performed by swapping the fluorescent dyes in the labeling of
cancer and control IgGs.
2.3. Analysis of the array data and identification of significant autoantibody biomarkers
The Cy5 and Cy3 images of the antibody array experiments of the eleven cancer plasma
samples were analyzed by GenePix Pro 6.0 microarray image analysis software (MDS Inc,
Toronto, Canada) to produce background-subtracted fluorescence intensity data. Log2-
transformed normalized fluorescence intensity ratios were median-centered and averaged for
the dye swapping experiments. Significance Analysis of Microarrays (SAM) method (30) were
first used to identify autoantibodies with statistically significant changes in intensity ratios
relative to normal, by assimilating a set of t-tests. Each autoantibody is assigned a test score
on the basis of its change in intensity relative to the standard deviation of repeated
measurements. The biomarkers were ranked according to the calculated false discovery rate,
with a false discovery rate of 3.832% as the cut-off point. The array data were also analyzed
using a normal mixture approach (31) for the detection of autoantibody biomarkers.
Transformed z-scores of one-sample t-statistics were clustered into the null group
(corresponding to antibodies that are not different between healthy and cancer samples) and
the non-null group (corresponding to antibodies that are different between healthy and cancer
samples). The ranking of biomarkers was based on the estimated posterior probability that an
individual antibody is null. Those biomarkers that were identified as significant in both methods
were then entered into the functional annotation and enrichment analysis. The SAM method
with two-class t-statistics was performed on the same dataset to identify autoantibody
biomarkers that segregate mucinous ovarian cancer patients with and without a smoking
history.
2.4. Functional annotation and enrichment analysis
Functional annotation and enrichment analysis of the biomarkers was performed using web-
based DAVID Functional Annotation Tool (http://david.abcc.ncifcrf.gov/summary.jsp).
GenBank accession numbers of the high-ranking biomarkers were submitted to the on-line
software to search for significant association of the biomarker clusters with relevant Gene
Ontolgoy (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.
2.5. Immunohistochemistry to determine the expression levels of pathway-specific tumor
antigens
A panel of five normal ovarian, ten borderline and fifteen invasive mucinous ovarian tumor
tissues were used for the immunohistochemical staining for pathway-specific tumor antigens.
7-□m sections were cut from the paraffin-archived tissues, mounted on Superfrost Plus
microscopic slides (Fisher Scientific, Pittsburgh, PA), and incubated at 50°C for 4 hr. The
sections were de-paraffinized in xylene and rehydrated with a descending series of ethanol.
For antigen unmasking, sections were immersed in antigen-unmasking solution (Vector
Laboratories, Burlingame, CA) and boiled in a microwave oven for 10 min. Endogenous
peroxidase activity was quenched using 0.3% H2O2 in methanol for 20 min. The sections were
then blocked with normal horse serum for 20 min and were subsequently incubated overnight
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with primary antibodies at 4°C. All primary antibodies were purchased from BD Biosciences
(San Jose, CA) and were used in 1:70-100 dilutions. After incubation, VECTASTAIN Elite
Avidin-Biotin Complex kit and the substrate diaminobenzidine (DAB) (Vector Laboratories,
Burlingame, CA) were used for color development. The sections were counterstained lightly
with hematoxylin (Fisher Scientific, Pittsburgh, PA), dehydrated with an ascending series of
ethanol, cleared in xylene, and mounted in Permount (Fisher Scientific, Pittsburgh, PA). The
staining was quantified with a semiquantitative scoring system. The weighted score was
obtained by multiplying the staining intensity score (3+, strong positive stain in cells; 2+,
moderate stain in cells; 1+, weak stain in cells; 0, no evidence of stain) and score for the
percentage of positive cells (3+, most of cells stained; 2+, half of cells stained; 1+, few cells
stained; 0, no cells stained). Two observers scored the slides independently, and the scores for
all cases were compared for discrepancies. The data obtained were analyzed by Mann-Whitney
test with MINITAB statistical software (Minitab, State College, PA) as the data were not
normally distributed. The staining of a tumor sample is considered as significantly different
from that of the normal ovaries when P < 0.05.
3. RESULTS
3.1. Autoantibody profiling of mucinous plasma by reverse capture antibody array platform
We explored the use of an innovative “reverse capture antibody array” method to profile the
autoantibodies of eleven cases of mucinous ovarian cancer plasma samples. The
clinicopathologic information of the patients is listed in Table S1. The “reverse capture
antibody array” method is based on the concept of dual-antibody sandwich ELISA assay (28,
32). This method (Figure S1) uses native protein antigens extracted from a pool of six mucinous
tumor tissues and captured by the monoclonal antibodies on a commercial high-density
antibody microarray as “baits” to bind fluorescently labeled human immunoglobulins (IgGs)
purified from patient and control plasma samples (29). The competitive binding between
patient and control antibodies to the antigens is visualized by fluorescence intensities of the
two dyes.
The results of a representative array experiment are presented in Figure 1. To control for any
labeling artifacts and confirm the differential antibody profiles, a second microarray
hybridization was performed by reversing the fluorescent dyes in the labeling of antibodies.
Authentic difference in the antibody titer will show reverse color change on the same spots in
the two arrays (Figure 1). Analysis of antibody array data using the analysis package
“Significance Analysis of Microarrays” (SAM) (30) resulted in the identification of thirty-
seven potential autoantibody biomarkers that are significantly elevated in the mucinous cases
as compared to normal controls (Figure 2a, and Table S2), and six autoantibody biomarkers
that can differentiate smoking and nonsmoking cases (Figure 2b). Furthermore, we also
analyzed the data using a normal mixture approach (31) for the detection of autoantibody
biomarkers, which is based on the clustering of transformed z-scores of t-statistics into the null
group (corresponding to antibodies that are not different between healthy and cancer samples)
and the non-null group (corresponding to antibodies that are different between healthy and
cancer samples). SAM generated false discovery rate for the identified marker list, whereas
the mixture approach provided the estimation of the posterior probability that an individual
antibody is null and hence the ranking of antibodies in decreasing order of the posterior
probabilities. Tables S2 and S3 present respectively the statistics of SAM, and the top ranking
autoantibodies of normal mixture model, respectively, for the autoantibodies that were elevated
in the mucinous cases. There are thirty-five such antibody biomarkers that are identified as
significant with the use of both SAM and the normal mixture approach (Table 1).
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3.2. Annotation analysis of the targets of identified antibody biomarkers
To interrogate the potential functions and the associated pathways of the targets of identified
antibody biomarkers in ovarian tumors, we performed a functional annotation and enrichment
analysis of the thirty-five autoantibody biomarkers using DAVID Functional Annotation Tool
(33). Functional annotation of the antibody targets suggested that mucinous ovarian plasma
samples are enriched with antibodies that target nucleoproteins, as in many autoimmune
diseases, as well as antibodies that target intracellular cell organization and signaling proteins
(Table 2). In particular, search in Kyoto Encyclopedia of Genes and Genomes (KEGG)
indicated significant enrichment of six elevated tumor autoantibodies that target antigens
involved in integrins-mediated pathway, and three tumor autoantibodies that target antigens in
Wnt signaling pathways (Table 3, and Figure S2).
3.3. Elevated expression of the pathway-associated antibody antigens in mucinous ovarian
tumors
The finding of autoantibodies in cancer plasmas that target integrins and Wnt signaling
pathways may suggest that these two pathways are deregulated in mucinous ovarian cancer.
To corroborate this finding, we employed antibodies that are specific to the marker antigens
in the immunohistochemical staining of a panel of archived ovarian specimens that include
normal ovaries, borderline and invasive mucinous ovarian tumors. The results of
immunohistochemistry (Figure 3) showed significant overexpression of all pathway-associated
tumor antigens except GIT1 in mucinous ovarian tumors, suggesting that these pathways might
be aberrantly activated in mucinous ovarian tumors and the host immune system might have
heightened reactivities with epitopes presented by these antigens.
4. DISCUSSION
The immune system of cancer patients actively monitors and elicits T-cell (34) and
autoantibody response to tumor-associated antigens (16,17). Detection of autoantibody
reactivity is useful in biomarker discovery and can reveal the identity of antigens that might
play a role in the pathophysiologic development of diseases. Some studies have shown that the
presence of serum autoantibodies is associated with changes in the antigens in human cancers
(21,35). Hence, screening of autoantibodies, whose levels significantly correlate with disease
status, may be beneficial to both diagnostic and therapeutic advances.
Several array-based screening platforms have been reported for autoantibody screening (24,
36). However, these protein microarrays employed recombinant proteins that may not have the
same posttranslational modifications and native configurations recognized by the
autoantibodies. It has been reported that removal of the carbohydrate moieties of Thomsen-
Friedenreich antigen caused the loss of binding of autoantibodies (37,38). Therefore, strategies
that employ native antigens derived from diseased materials may add significant value to
identify the authentic autoantibody-antigen reactivities. We have applied an innovative
reverse-capture antibody array platform that uses tumor tissue-derived native protein antigens
captured on an antibody microarray (29) to profile autoantibody biomarkers. The use of two
methods to analyze the array data has allowed us to identify thirty-five autoantibodies that were
elevated in cancer cases (Table 1). Functional annotation and enrichment analysis of these
autoantibody biomarkers have shown that the tumor antigen targets for these autoantibodies
are composed of nucleoproteins and intracellular cell organization and signaling proteins.
Significantly, we found an enrichment of nine autoantibody antigens in the integrin pathway
that regulates actin cytoskeleton and cell invasion (Figure S2a), and beta-catenin-mediated
Wnt signaling pathway (39) that is important during development and oncogenesis (Figure
S2b). Immunohistochemistry has revealed significant overexpression of eight of the nine
antigens in both borderline and invasive mucinous ovarian tumors (Figure 3), While the GIT1
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antigen did not show significant overexpression in mucinous ovarian tumors, it is possible that
the antigen underwent other changes such as mutations during pathogenesis that were not
revealed by immunohistochemistry. Integrin receptors for fibronectin are important for the
response of ovarian carcinoma to matrix microenvironment and metastasis (40,41). Some
markers such as alpha 2-integrins are involved in the dissemination of mucinous
cystadenocarcinoma (42), and the expression of Wnt signaling protein beta-catenin was found
distinctively high in the membrane and cytoplasm of mucinous tumors (43,44). Hence
overexpression of tumor antigens involved in these two pathways in mucinous ovarian tumors
may suggest that deregulation of both integrin and Wnt signaling pathways are important to
pathogenic development of human mucinous ovarian cancer and likely stimulate the immune
system to produce the autoantibody biomarkers identified by this autoantibody screen.
Epidemiologic studies have indicated that women with tobacco exposure have significant risk
of developing mucinous ovarian cancer (11-13). We therefore have analyzed the reverse
capture antibody array data to determine if there are autoantibody biomarkers that can
distinguish between smoking and nonsmoking mucinous cancers. Two-class SAM analysis
has identified six antibodies that are significantly different between these two groups of
mucinous cancer samples (Figure 2b). These antibody targets play important roles in the
homeostasis of different biological processes such as DNA repair (three prime repair
exonuclease 1), glucose metabolism (Aralar 1), and cell cycle regulation (cyclin-dependent
kinase 4). Moreover, these proteins have been reported to be involved in autoimmunity
(45-48). We are currently performing studies to further evaluate if the identified marker targets
can reveal any mechanistic differences underlying smoking and nonsmoking mucinous ovarian
cancer.
In conclusion, our autoantibody profiling in mucinous ovarian cancer using the innovative
reverse capture antibody array platform has identified thirty-five autoantibody biomarkers.
Nine of the autoantibody targets are associated with tumor antigens involved in integrins and
Wnt signaling pathways. Autoantibody profiling may have substantial utility in identifying
key signaling pathways that are deregulated in cancer and other diseases.
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Figure 1. Representative figure of an antibody array experiment
Antibodies that are elevated in cancer plasma are green in array 1 and red in array 2. Some of
the identified autoantibody biomarkers are marked as shown.
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Figure 2. Autoantibody biomarkers for mucinous ovarian cancer determined by “Significance
Analysis of Microarrays”
The heat maps show (a) autoantibodies that are significantly different between cancer cases
and healthy control; and (b) autoantibodies that are significantly different between smoking
and non-smoking group.
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Figure 3. Immunohistochemistry for the expression of pathway-specific tumor antigens
Representative micrographs of immunohistochemical staining of normal, borderline and
invasive mucinous ovarian tumor sections are shown. The names of the tumor antigens and
the P-values for the Mann-Whitney analysis of the immunohistochemical results are shown on
the left.
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Table 1
The list of thirty-five autoantibody biomarkers that are significant with both “Significance Analysis of
Microarrays” and the normal mixture approaches.
ID Accession Number Fold-changesrelative to normal
casein kinase 1, epsilon P49674 2.529
CSE1 chromosome segregation 1-like (yeast) P55060 2.49
topoisomerase (DNA) II alpha 170KDa P11388 2.462
v-crk sarcoma virus CT10 oncogene homolog
(avian) P46108 2.254
RAS p21 protein activator (GTPase activating
protein)1 P20936 2.085
G protein-coupled receptor 51 O75899 2.053
WAS protein family, member 1 Q92558 2.032
fibronectin 1 P02751 1.969
integrin, alpha 2 (CD49B, alpha 2 subunit of
VLA-2 receptor) P17301 1.895
solute carrier family 9 (sodium/hydrogen
exchanger), isoform 1 (antiporter, Na+/H+,
amiloride sensitive)
P19634 1.834
zeta-chain (TCR) associated protein kinase 70kDa P43403 1.812
translin-associated factor X Q99598 1.793
eukaryotic translation initiation factor 4 gamma,
1 Q04637 1.775
glutamate receptor, ionotropic, N-methyl D-
aspartate 2B Q13224 1.753
syntaxin binding protein 5 (tomosyn) Q5T5C0 1.667
dystrophia myotonica-protein kinase Q09013 1.659
syntaxin 6 O43752 1.623
Ras-GTPase-activating protein SH3-domain-
binding protein Q13283 1.617
catenin (cadherin-associated protein), beta 1,
88kDa P35222 1.615
non-metastatic cells 1, protein (NM23A)
expressed in P15531 1.589
transcription factor 3 (E2A immunoglobulin
enhancer binding factors E12/E47) P15923 1.583
TATA box binding protein P20226 1.534
neural precursor cell expressed, developmentally
down-regulated 4 P46934 1.496
heme oxygenase (decycling) 1 P09601 1.47
special AT-rich sequence binding protein 1 (binds
to neclear matrix/scaffold-associating DNA’s) Q01826 1.468
endothelin receptor type A P25101 1.468
karyopherin (importin) beta 1 Q14974 1.452
G protein-coupled receptor kinase-interactor 1 Q9Y2X7 1.418
MCM4 minichromosome maintenance deficient 4
(S. cerevisiae) P33991 1.404
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ID Accession Number Fold-changesrelative to normal
lymphocyte-specific protein tyrosine kinase P06239 1.398
protein phosphatase 1G (formerly 2C),
magnesium-dependent, gamma isoform O15355 1.388
vesicle transport through interaction with t-
SNAREs 1B homolog Q9UEU0 1.375
C-terminal binding protein 2 P56545 1.335
DEK oncogene (DNA binding) P35659 1.264
sorting nexin 1 Q13596 1.232
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Table 2
Functional annotation and enrichment analysis of the autoantibody targets.
Nuclear Proteins (N=17)
Term Counta Fold-Enrichmentb P_Valuec
Nucleobase, nucleoside, nucleotide and
nucleic acid metabolism 11 2.6 1.20E-05
DNA-dependent ATPase activity 3 54.4 1.20E-03
DNA-binding 7 4.1 3.20E-03
Cell proliferation 5 6 6.20E-03
Regulation of transcription 8 3 7.10E-03
Cell death 5 5.8 7.30E-03
Response to DNA damage stimulus 3 8.9 3.90E-02
Cytoplasmic and Plasma Membrane Proteins (N=29)
Term Counta Fold-Enrichmentb P_Valuec
Cytoplasmic and Plasma Membrane Proteins (N=29)
Intracellular signaling cascade 12 4.4 2.20E-05
Receptor complex 4 25.4 4.60E-04
Cell communication 16 2.1 1.50E-03
Vesicle-mediated transport 6 6.5 1.70E-03
cell proliferation 7 4.8 2.20E-03
Hydrolase activity, acting on ester
bonds 6 4.8 6.50E-03
Apoptosis 6 4.2 1.10E-02
Cell Surface Receptor-linked Signal
Transduction 8 2.3 3.80E-02
Annotated gene functions were determined by searches in Gene Ontology.
a
the number of antigens belonging to an annotation term.
b
The ratio of the number of antigens described by the term category over total number of antigens in the list relative to the ratio of proteins with the
same term category in the human genome background
c
, modified Fisher Exact P-value to measure the enrichment in annotation terms.
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Table 3
Enrichment analysis of the autoantibody targets in pathways by searches in Kyoto Encyclopedia of Genes and
Genomes (KEGG) Pathway Databases.
Term Counta Fold-Enrichmentb P_Valuec Genes
Wnt signaling pathway 3 12 1.70E-02 Catenin (cadherin-associated
protein), beta 1, 88kda
Casein kinase 1, epsilon
C-terminal binding protein 2
Regulation of actin
cytoskeleton
6 5.9 2.10E-03 Integrin, alpha 2 (CD49B,
alpha 2 subunit of VLA-2
receptor)
Fibronectin 1
NHE-1
V-crk sarcoma virus CT10
oncogene homolog (avian)
G protein-coupled receptor
kinase-interactor 1
WAS protein family, member
1
Annotated gene functions were determined by searches in Gene Ontology.
a
the number of antigens belonging to an annotation term.
b
The ratio of the number of antigens described by the term category over total number of antigens in the list relative to the ratio of proteins with the
same term category in the human genome background
c
, modified Fisher Exact P-value to measure the enrichment in annotation terms.
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